Exelixis Announces Submission of sNDA to US FDA for CABOMETYX®
Exelixis (EXEL) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. FDA for CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) for patients with advanced renal cell carcinoma (RCC).
According to Gisela Schwab, M.D., President, Product Development and Medical . . .
This content is for paid subscribers.
Today’s Highlights August 25, 2020